[Dopamine agonists--clinical applications beyond Parkinson's disease].
Contemporary experience and results of clinical trials concerning dopamine agonist application in the treatment of many different diseases (apart from Parkinson's disease) are presented in the paper. A basic clinical recommendation for agonists is restless legs syndrome. In this syndrome almost all agonists give a considerable subjective and objective improvement. Treatment of atypical parkinsonism (MSA, PSP, CBD) in the majority of patients is ineffective. The author also presents promising results of treatment with agonists in such diverse diseases as hyperkinetic syndromes, cocaine dependence, drug-resistant depression and erectile dysfunction (apomorphine). Dopamine partial agonists (e.g. aripiprazol) are recommended in the modern treatment of schizophrenia.
Kuran
Włodzimierz
W
I Klinika Neurologiczna Instytutu Psychiatrii i Neurologii w Warszawie. neurol1@ipin.edu.pl
D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D019970:Cocaine-Related Disorders / Q000188:drug therapy; D003866:Depressive Disorder / Q000188:drug therapy; D018491:Dopamine Agonists / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D008297:Male; D012148:Restless Legs Syndrome / Q000188:drug therapy*; D012559:Schizophrenia / Q000188:drug therapy*; D016896:Treatment Outcome
D018491:Dopamine Agonists